Abstract
Cervical cancer, the third most common cancer in women worldwide, has an incidence of 80 % in the developing countries. Relatively, the women in developing nations are diagnosed at an advanced stage of the disease due to disparities in screening programs and other socio-economic factors. Although surgery and/or chemo, radiotherapies are indicated for early stage cervical cancers, in the advanced stages, palliative management continues to be the mainstay approach. Recent approaches exploring targeted therapies that act on receptors, signalling pathways, molecules deserve a mention. Autologous immune-cell-based immunotherapies for cancer have been in clinical practice for more than three decades in countries like Japan for various solid tumors including cervical cancer. The cell based immunotherapies employ dendritic Cells, γδ T cells (gamma delta T cells) natural killer (NK) cells, NKT cells, activated T lymphocytes, cytotoxic T lymphocytes (CTLs) and lymphokine activated killer (LAK) cells. NK cells are of particular interest due to their rapid response against cancer cells and virus-infected cells even without being sensitized to antigens to kill cells that are missing the “self” markers of the major histocompatibility complex (MHC) class I. With human papilloma virus (HPV) being associated with virtually all the cases of cervical cancer, NK cell immunotherapy gathers more importance as it acts as a common weapon against the virus and cancer cells. With vaccination against HPV now being available, immunological considerations in cervical cancer gain significance and form a major arena for future research. This chapter will provide an overview on the existing treatment options for cervical cancer with special emphasis on the cell-based immunotherapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hajdu SI (2004) Greco-Roman thought about cancer. Cancer 100:2048–2051
Khaled HM (2006) Breast cancer at diagnosis in women of Africa and the Middle East. In: Williams CKO, Olopade OI, Falkson CI (eds) Breast cancer in women of African descent. Springer, Dordrecht, pp 81–90. doi:10.1007/978-1-4020-3664-4_5
Globocan (2008) Cancer fact sheet (cited 24 Jan 2014). Available from: http://globocan.iarc.fr/factsheets/cancers/cervix.asp
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19
Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244–265
Franco EL, Duarte-Franco E, Ferenczy A (2001) Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J 164:1017–1025
Burd EM (2003) Human papillomavirus and cervical cancer. Clin Microbiol Rev 16:1–17
Information from Cancer.org (cited 24 Jan 2014). Available from: http://www.cancer.org/cancer/cervicalcancer/moreinformation/cervicalcancerpreventionandearlydetection/cervical-cancer-prevention-and-early-detection-cervical-cancer-signs-and-symptoms. Last Reviewed 17 Sep 2014
Denny L, Hacker NF, Gori J, Jones HW III, Ngan HYS, Pecorelli S (2000) Staging classifications and clinical practice guidelines for gynaecological cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet 70:207–312, [cited 24 Jan 2014]. Available from: http://www.figo.org/files/figo-corp/docs/staging_booklet.pdf
Petsuksiri J, Jaishuen A, Pattaranutaporn P, Chansilpa Y (2012) Advanced imaging applications for locally advanced cervical cancer. Asian Pac J Cancer Prev 13:1713–1718
Information from National Cancer Institute (cited 24 Jan 2014). Available from: http://www.cancer.gov/types/cervical/pap-hpv-testing-fact-sheet. Reviewed 9 Sep 2014
Canavan TP, Doshi NR (2000) Cervical cancer. Am Fam Physician 61:1369–1376
Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154–1161, Erratum in: N Engl J Med 1999; 341:708
Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153, Erratum in: N Engl J Med 1999; 341 :708
Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143
Kim HS, Sardi JE, Katsumata N, Ryu HS, Nam JH, Chung HH, Park NH, Song YS, Behtash N, Kamura T, Cai HB, Kim JW (2013) Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol 39:115–124
Seth R, Tai LH, Falls T, de Souza CT, Bell JC, Carrier M, Atkins H, Boushey R, Auer RA (2013) Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model. Ann Surg 258:158–168
Peralta-Zaragoza O, Bermúdez-Morales VH, Pérez-Plasencia C, Salazar-León J, Gómez-Cerón C, Madrid-Marina V (2012) Targeted treatments for cervical cancer: a review. Onco Targets Ther 5:315–328
Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A (2013) Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit Rev Oncol Hematol 85:303–314
Sekla B, Holeckova E (1959) Trials at immunotherapy of a transplanted cancer. Acta Unio Int Contra Cancrum 15:976–979
Cinader B, Hayley MA, Rider WD, Warwick OH (1961) Immunotherapy of a patient with choriocarcinoma. Can Med Assoc J 84:306–309
Mathé G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M (1965) Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 25:1525–1531
Egawa K (2004) Immuno-cell therapy of cancer in Japan. Anticancer Res 24:3321–3326
Lindahl P, Leary P, Gresser I (1972) Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci U S A 69:721–725
Kirkpatrick CH (1993) Structural nature and functions of transfer factors. Ann N Y Acad Sci 685:362–368
Blume MR, Rosenbaum EH, Cohen RJ, Gershow J, Glassberg AB, Shepley E (1981) Adjuvant immunotherapy of high risk stage I melanoma with transfer factor. Cancer 47:882–888
Wagner G, Gitsch E, Havelec L, Knapp W, Rainer H, Selander S (1983) Transfer factor as adjuvant immunotherapy in invasive cervix cancer. Report of a double-blind study. Wien Klin Wochenschr 95:738–742
de Kernion JB, Sarna G, Figlin R, Lindner A, Smith RB (1983) The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 130:1063–1066
Pizza G, Severini G, Menniti D, De Vinci C, Corrado F (1984) Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer 34:359–367
Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD et al (1985) Intraperitoneal recombinant alpha-interferon for “salvage” immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer Res 45:4447–4453
Goldberg RM, Ayoob M, Silgals R, Ahlgren JD, Neefe JR (1985) Phase II trial of lymphoblastoid interferon in metastatic malignant melanoma. Cancer Treat Rep 69:813–816
Legha SS (1986) Interferons in the treatment of malignant melanoma. A review of recent trials. Cancer 57:1675–1677
Rosenberg SA (1986) Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. J.B. Lippincott, New York, pp 55–91
Ettinghausen SE, Rosenberg SA (1986) The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Springer Semin Immunopathol 9:51–71
van den Brink MR, Voogt PJ, Marijt WA, van Luxemburg-Heys SA, van Rood JJ, Brand A (1989) Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. Blood 74:354–360
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C (1986) A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery 100:262–272
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492
Koretz MJ, Lawson DH, York RM, Graham SD, Murray DR, Gillespie TM, Levitt D, Sell KM (1991) Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 126:898–903
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897
Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 48:206–214
Moy PM, Holmes EC, Golub SH (1985) A method for improved yield and purity in extracting lymphocytes from lung tumors. J Surg Res 38:17–23
Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P et al (1988) Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 6:839–853
Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318–1321
Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ et al (1989) Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1:577–580
Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474–484
Mulder WM, Stukart MJ, Roos M, van Lier RA, Wagstaff J, Scheper RJ, Bloemena E (1995) Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity. Cancer Immunol Immunother 41:293–301
Schöndorf T, Engel H, Lindemann C, Kolhagen H, von Rücker AA, Mallmann P (1997) Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours. Cancer Immunol Immunother 44:88–96
Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296
Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ (2008) Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 82:1968–1979
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332
Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Bröcker EB, Steinman RM, Enk A, Kämpgen E, Schuler G (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669–1678
Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, Veelken H (2006) Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 119:2428–2434
Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G, Giesler JM, Jüttner E, Peters JH, Häring B, Leo R, Unger C, Azemar M (2007) Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells – a pilot study. Prostate 67:500–508
Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Murphy GP (1998) Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol 18:109–119
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) IMPACT study investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, Urdal DL (2013) Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 62:137–147
Malarkey MA, FDA approval letter – provenge (cited 24 Jan 2014). Available from: http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210215.htm
Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Dürst M, Schneider A, Kaufmann AM (2003) Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 129:521–530
Ye F, Yu Y, Hu Y, Lu W, Xie X (2010) Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma. J Exp Clin Cancer Res 29:78
Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labbé J, Bonnotte B (2011) Dendritic cell-tumor cell hybrids and immunotherapy: what’s next? Cytotherapy 13:774–785
Berezhnaya NM, Vinnichuk UD, Konovalenko VF, Vorobjova LI, Belova OB, Proskurnia LA (2005) The sensitivity of chemioresistant human tumor explants to lysis by activated and nonactivated autological lymphocytes: a pilot study. Exp Oncol 27:303–307
Verma V, Sharma V, Shrivastava SK, Nadkarni JJ (2000) IL-12 and IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients. J Exp Clin Cancer Res 19:367–374
Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N (2008) Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol 27:93–110
Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence an 11-year follow-up study of a general population. Lancet 356:1795–1799
Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, Toi M, Yamamoto N (2007) Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat 104:267–275
Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res 10:3699–3707
Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T (2004) Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 24:1861–1871
Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N, Toi M (2011) Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer 18:64–67
Seltzer V, Doyle A, Kadish AS (1983) Natural cytotoxicity in malignant and premalignant cervical neoplasia and enhancement of cytotoxicity with interferon. Gynecol Oncol 15:340–349
Amador-Molina A, Hernández-Valencia JF, Lamoyi E, Contreras-Paredes A, Lizano M (2013) Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses 5:2624–2642
Radhakrishna Pillai M, Balaram P, Padmanabhan TK, Abraham T, Krishnan Nair M (1989) Interleukin 2 and alpha interferon induced in vitro modulation of spontaneous cell mediated cytotoxicity in patients with cancer of the uterine cervix undergoing radiotherapy. Acta Oncol 28:39–44
Cosiski Marana HR, Santana da Silva J, Moreira de Andrade J (2000) NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 78:318–323
Rutella S, Iudicone P, Bonanno G, Fioravanti D, Procoli A, Lavorino C, Foddai ML, Lorusso D, Martinelli E, Vacca M, Ipsevich F, Nuti M, Scambia G, Pierelli L (2012) Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy 14:841–850
Premkumar S, Dedeepiya VD, Terunuma H, Senthilkumar R, Srinivasan T, Reena HC, Preethy S, Abraham SJ (2013) Cell based autologous immune enhancement therapy (AIET) after radiotherapy in a locally advanced carcinoma of the cervix. Case Rep Oncol Med 2013:903094
Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13:98–107
Meller B, Frohn C, Brand JM, Lauer I, Schelper LF, von Hof K, Kirchner H, Richter E, Baehre M (2004) Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging 31:403–407
Cheng M, Chen Y, Xiao W, Sun R, Tian Z (2013) NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 10:230–252
Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, Alva JA, Walter G, Head C, Ishikawa TO, Herschman HR, Cacalano N, Pyle AD, Park NH, Jewett A (2010) Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One 5:e11590
Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, Bottino C (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182:3530–3539
Zhang SL, Wang YS, Zhou T, Yu XW, Wei ZT, Li YL (2012) Isolation and characterization of cancer stem cells from cervical cancer HeLa cells. Cytotechnology 64:477–484
Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284
Maher J, Davies ET (2004) Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br J Cancer 91:817–821
Wright SE, Rewers-Felkins KA, Quinlin IS, Phillips CA, Townsend M, Philip R, Dobrzanski MJ, Lockwood-Cooke PR, Robinson W (2012) Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother 35:196–204
Verdegaal EM, Visser M, Ramwadhdoebé TH, van der Minne CE, van Steijn JA, Kapiteijn E, Haanen JB, van der Burg SH, Nortier JW, Osanto S (2011) Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother 60:953–963
Lee YS, Kim TS, Kim DK (2011) T lymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor. BMC Cancer 11:225
Liao T, Kaufmann AM, Qian X, Sangvatanakul V, Chen C, Kube T, Zhang G, Albers AE (2013) Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J Cancer Res Clin Oncol 139:159–170
Holtmeier W, Kabelitz D (2005) Gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy 86:151–183
Gertner J, Wiedemann A, Poupot M, Fournié JJ (2007) Human gammadelta T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett 110:42–53
Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K (2011) Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 60:1075–1084
Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M (2011) Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 105:778–786
Li H, Wang Y, Zhou F (2010) Effect of ex vivo-expanded γδ-T cells combined with galectin-1 antibody on the growth of human cervical cancer xenografts in SCID mice. Clin Invest Med 33:E280–E289
Jerud ES, Bricard G, Porcelli SA (2006) CD1d-restricted natural killer T cells: roles in tumor immunosurveillance and tolerance. Transfus Med Hemother 33:18–36
Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL, Blumberg RS (2012) Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336:489–493
Terabe M, Berzofsky JA (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101:277–348
Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T (2006) A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12:6079–6086
Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M, Motohashi S, Nakayama T, Okamoto Y (2011) Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 138:255–265
Melnick JL (1976) Immunological control of cervical cancer: discussion. Cancer Res 36:859–860
Pimenta JM, Galindo C, Jenkins D, Taylor SM (2013) Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer 13:553
Rey-Ares L, Ciapponi A, Pichon-Riviere A (2012) Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: systematic review and meta-analysis. Arch Argent Pediatr 110:483–489
Trimble CL, Frazer IH (2009) Development of therapeutic HPV vaccines. Lancet Oncol 10:975–980
Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838–1847
Mikysková R, Indrová M, Símová J, Jandlová T, Bieblová J, Jinoch P, Bubeník J, Vonka V (2004) Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol 24:161–167
Renoux VM, Bisig B, Langers I, Dortu E, Clémenceau B, Thiry M, Deroanne C, Colige A, Boniver J, Delvenne P, Jacobs N (2011) Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur J Immunol 41:3240–3252
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907
Shanker A, Marincola FM (2011) Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother 60:1061–1074
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Abraham, S.J.K., Terunuma, H., Dedeepiya, V.D., Premkumar, S., Preethy, S. (2015). An Overview of Treatment for Cervical Cancer with Emphasis on Immune Cell-Based Therapies. In: de Mello, R., Tavares, Á., Mountzios, G. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-21683-6_44
Download citation
DOI: https://doi.org/10.1007/978-3-319-21683-6_44
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-21682-9
Online ISBN: 978-3-319-21683-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)